Cogent Biosciences Inc. (NASDAQ:COGT) shares are up on Monday after the U.S. Food and Drug Administration accepted its drug application for bezuclastinib.

FDA Decision Expected In December 2026

The U.S. Food and Drug Administration (FDA) on Monday accepted Cogent’s New Drug Application (NDA) for bezuclastinib, targeting Non-Advanced Systemic Mastocytosis (Non-AdvSM).

NonAdvSM is a rare, chronic disorder characterized by abnormal mast cell accumulation in different organs in the body.

The Prescription Drug User Fee Act (PDUFA) action date is set for December 30, 2026.

The FDA has indicated no plans for an advisory committee meeting, suggesting a smoother review process.

Encouraging Trial Data

Clinical data from the pivotal SUMMIT trial showed significant improvements across key endpoints for patients treated with bezuclastinib, highlighting its potential for chronic use and favorable safety profile.

Data from the SUMMIT trial through 48 weeks showcased a clear and continued deepening of symptomatic improvement over time, supporting the potential for sustained clinical benefit with longer duration of therapy.

Regulatory Pathway

The company is also on track to submit NDAs for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST) by April 2026 and for Advanced Systemic Mastocytosis (AdvSM) in the first half of 2026.

In January, the FDA granted Breakthrough Therapy Designation (BTD) to Cogent Biosciences’ bezuclastinib in combination with sunitinib for GIST patients.

Cogent Biosciences Technical Analysis

The stock is currently trading 4.6% below its 20-day simple moving average (SMA) but is 3.8% above its 100-day SMA, demonstrating some longer-term strength. Shares have increased 380.31% over the past 12 months and are currently positioned closer to their 52-week highs than lows.

The RSI is at 32.77, which is considered neutral territory. Meanwhile, MACD is at -0.5556, below its signal line at -0.1256, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.

  • Key Resistance: $41.00
  • Key Support: $35.50

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $32.27. Recent analyst moves include:

  • Piper Sandler: Overweight (Raises Target to $52.00) (Feb. 18)
  • Wedbush: Outperform (Maintains Target to $55.00) (Jan. 21)
  • HC Wainwright & Co.: Buy (Raises Target to $52.00) (Jan. 6)

Cogent Biosciences Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Cogent Biosciences, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: Bullish (Score: 99.12) — Stock is outperforming the broader market.

The Verdict: Cogent Biosciences’ Benzinga Edge signal reveals a strong momentum score, indicating that the stock is currently outperforming the broader market. This bullish momentum, combined with the recent FDA news, positions Cogent favorably for potential future gains.

Cogent Biosciences Top ETF Exposure

  • iShares Microcap ETF (NYSE:IWC): 1.05% Weight
  • Tema Oncology ETF (NASDAQ:CANC): 3.26% Weight
  • F/m Emerald Life Sciences Innovation ETF (NASDAQ:LFSC): 8.90% Weight

COGT Price Action: Cogent Biosciences shares were up 5.24% at $35.78 at the time of publication on Monday, according to Benzinga Pro data.

Image via Shutterstock